Asthma is a fairly common complaint worldwide. Usually related to, or triggered by allergies, treatments vary depending on severity. Obviously, most doctors prescribe a form of inhalent for day to day management. Alternatively, liquid inhalants may be prescribed and administered via a nebuliser. Now, new research indicates it might help with the treatment of COVID-19.
Ashma’s commonly prescribed Pulmicort
Asthma and its treatment appear to be providing some relief to COVID-19 patients. On July 13th, HospiMedica released an article citing a study on the use of asthma treatments for COVID-19. Initially, the medication got flagged by USA-based Dr Richard Bartlett. He prescribes inhalants in their nebulizer, liquid form to patients. He says patients report improvement within hours. Australia’s The Queensland University of Technology (QUT) combined forces with Oxford University. They formed a research team currently conducting trials in the UK.
Pulmicort is a widely available inhalant in powder form which contains Budesonide. That is the active ingredient prescribed by Dr Bartlett. As a result of this, the research team suggested all patients showing initial symptoms of a dry cough should get Budesonide prescribed. However, not as a cure, but as a precautionary medication pending the outcome of the trials.
The medical profession advise caution
Dr Michael Peters, an Assistant Professor from the School of Medicine at Californa University urges caution pending results of clinical trials. Obviously, professionals require caution, especially in times of pandemics. All the same, many agree that that Budesonide shows promise. Undoubtedly, they follow clinical trials closely.
By the same token, can people wait for clinical trials? Dr Bartlett says no. Notably, use of the medication’s not a cure. Indeed, he simply says that early treatment with liquid Budesonide clearly offers fast relief to patients. Other doctors claim Pulmicort get prescribed immediately when COVID-19 presents anyway. To clarify, Barlett says too much of the common inhalant doesn’t reach the lungs whereas the nebulized form does.
Twitter came alive with people calling this the ‘silver bullet’. However, Dr Bartlett says it’s not a cure, only a seemingly effective treatment.
In summary, asthmatics initially got flagged as high-risk from COVID-19. Importantly, their illness may prove a breakthrough treatment for the pandemic.
Have your say. Do you want your doctor to prescribe Budesonide for your dry cough?
Remember to check back with SANs Newsfeed often for more news about Africa.